Research ExplorerPublicationsImmunopathology of multiple sclerosis

Immunopathology of multiple sclerosis

Standard

Immunopathology of multiple sclerosis. / Dendrou, Calliope A; Fugger, Lars; Friese, Manuel A.

In: NAT REV IMMUNOL, Vol. 15, No. 9, 15.09.2015, p. 545-58.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dendrou, CA, Fugger, L & Friese, MA 2015, 'Immunopathology of multiple sclerosis', NAT REV IMMUNOL, vol. 15, no. 9, pp. 545-58. https://doi.org/10.1038/nri3871

APA

Dendrou, C. A., Fugger, L., & Friese, M. A. (2015). Immunopathology of multiple sclerosis. NAT REV IMMUNOL, 15(9), 545-58. https://doi.org/10.1038/nri3871

Vancouver

Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. NAT REV IMMUNOL. 2015 Sep 15;15(9):545-58. https://doi.org/10.1038/nri3871

Bibtex

@article{3ba593c3e7ac4347b6662ac11a61edcb,
title = "Immunopathology of multiple sclerosis",
abstract = "Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis point to distinct immunological pathways that drive disease relapses and progression. In light of this, we discuss our current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. Recent and anticipated advances in the field of immunology, and the increasing recognition of inflammation as an important component of neurodegeneration, are shaping our conceptualization of disease pathophysiology, and we explore the potential implications for improved healthcare provision to patients in the future.",
author = "Dendrou, {Calliope A} and Lars Fugger and Friese, {Manuel A}",
year = "2015",
month = sep,
day = "15",
doi = "10.1038/nri3871",
language = "English",
volume = "15",
pages = "545--58",
journal = "NAT REV IMMUNOL",
issn = "1474-1733",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Immunopathology of multiple sclerosis

AU - Dendrou, Calliope A

AU - Fugger, Lars

AU - Friese, Manuel A

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis point to distinct immunological pathways that drive disease relapses and progression. In light of this, we discuss our current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. Recent and anticipated advances in the field of immunology, and the increasing recognition of inflammation as an important component of neurodegeneration, are shaping our conceptualization of disease pathophysiology, and we explore the potential implications for improved healthcare provision to patients in the future.

AB - Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis point to distinct immunological pathways that drive disease relapses and progression. In light of this, we discuss our current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. Recent and anticipated advances in the field of immunology, and the increasing recognition of inflammation as an important component of neurodegeneration, are shaping our conceptualization of disease pathophysiology, and we explore the potential implications for improved healthcare provision to patients in the future.

U2 - 10.1038/nri3871

DO - 10.1038/nri3871

M3 - SCORING: Journal article

C2 - 26250739

VL - 15

SP - 545

EP - 558

JO - NAT REV IMMUNOL

JF - NAT REV IMMUNOL

SN - 1474-1733

IS - 9

ER -